Theracurmin®

Nano-Curcumin Inhibits Proliferation of Esophageal Adenocarcinoma Cells and Enhances the T Cell Mediated Immune Response.

Milano F, Mari L, van de Luijtgaarden W, Parikh K, Calpe S, Krishnadath KK.

Front Oncol. 2013 May 29; 3: 137.

Highly bioavailable curcumin (Theracurmin): its development and clinical application.

Imaizumi A.

PharmaNutrition. 2015 Oct; 3 (4): 123–130.

Theracurmin^® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest.

Kang M, Ho JN, Kook HR, Lee S, Oh JJ, Hong SK, Lee SE, Byun SS.

Oncol Rep. 2016 Mar; 35 (3): 1463-1472. doi org/10.3892/or.2015.4537.

Novel Curcumin Oral Delivery Systems.

Kurita T, Makino Y.

Anticancer Res. 2013; 33 (7): 2807-2822.

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.

Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H.

Cancer Chemother Pharmacol. 2013 Jun; 71 (6): 1521-1530.

Clinical Application of “Curcumin”, a Multi-Functional Substance.

Shimatsu A, Kakeya H, Imaizumi A, Morimoto T, Kanai M, Maeda S.

Anti-Aging Medicine . 2012 Mar; 9(2): 75-83.